Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Shaughnessy JD Jr, et al. Among authors: mohiuddin a. Br J Haematol. 2007 Jun;137(6):530-6. doi: 10.1111/j.1365-2141.2007.06586.x. Epub 2007 May 9. Br J Haematol. 2007. PMID: 17489983 Free article.
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. Shaughnessy JD Jr, et al. Among authors: mohiuddin a. Blood. 2007 Mar 15;109(6):2276-84. doi: 10.1182/blood-2006-07-038430. Epub 2006 Nov 14. Blood. 2007. PMID: 17105813 Free article.
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Walker R, et al. Among authors: mohiuddin a. J Clin Oncol. 2007 Mar 20;25(9):1121-8. doi: 10.1200/JCO.2006.08.5803. Epub 2007 Feb 12. J Clin Oncol. 2007. PMID: 17296972 Clinical Trial.
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr. Barlogie B, et al. Among authors: mohiuddin a. Br J Haematol. 2007 Jul;138(2):176-85. doi: 10.1111/j.1365-2141.2007.06639.x. Br J Haematol. 2007. PMID: 17593024 Free article. Clinical Trial.
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Barlogie B, et al. Among authors: mohiuddin a. Blood. 2008 Jan 1;111(1):94-100. doi: 10.1182/blood-2007-06-097444. Epub 2007 Sep 25. Blood. 2008. PMID: 17895401 Free PMC article.
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Haessler J, et al. Among authors: mohiuddin a. Clin Cancer Res. 2007 Dec 1;13(23):7073-9. doi: 10.1158/1078-0432.CCR-07-0527. Clin Cancer Res. 2007. PMID: 18056185 Clinical Trial.
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. van Rhee F, et al. Among authors: mohiuddin a. Blood. 2007 Aug 1;110(3):827-32. doi: 10.1182/blood-2007-01-067728. Epub 2007 Apr 6. Blood. 2007. PMID: 17416735 Free PMC article. Clinical Trial.
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. Girnius SK, et al. Among authors: mohiuddin a. Br J Haematol. 2015 Apr;169(1):36-43. doi: 10.1111/bjh.13243. Epub 2015 Jan 8. Br J Haematol. 2015. PMID: 25572917 Free article. Clinical Trial.
153 results